PharmaVoice 100: Page 2
-
Profile // PharmaVoice 100
Disrupters: Carl Turner
How Klick’s first-ever chief brand strategy officer is relying on collaboration to advance innovative strategies for clients and opportunities for people of color.
By Meagan Parrish • Sept. 6, 2022 -
Profile // PharmaVoice 100
Legacy Leaders: Carol Lynch
The chief business officer for Sandoz combines a shrewd business sense with a generous approach to leadership.
By Alexandra Pecci • Sept. 6, 2022 -
Profile // PharmaVoice 100
Disrupters: Charlene Stern
How the chief lawyer of Editas Medicine is using a multi-lens approach to bolster the development of game-changing genomic medicines.
By PharmaVoice staff • Sept. 6, 2022 -
Profile // PharmaVoice 100
Legacy Leaders: Chris Round
The president of EMD Serono, the U.S. and Canadian healthcare business unit of Merck KGaA, Darmstadt, Germany, has the company firing on all cylinders for near- and long-term growth.
By PharmaVoice staff • Sept. 6, 2022 -
Profile // PharmaVoice 100
Innovators: Dr. Cristian Massacesi
With the goal of redefining how medicines are made, the CMO and oncology CDO is transforming AstraZeneca’s oncology development.
By Meagan Parrish • Sept. 6, 2022 -
Profile // PharmaVoice 100
Entrepreneurs: David Katz
As the founder and chief scientific officer of Sparrow Pharmaceuticals, David Katz is breathing new life into drugs that have previously been shelved.
By Michael Gibney • Sept. 6, 2022 -
Profile // PharmaVoice 100
Entrepreneurs: Dawn Barry
The co-founder and president of LunaPBC is seeking to eliminate the middlemen in drug development by connecting patients — and their real-world data — directly with researchers.
By PharmaVoice staff • Sept. 6, 2022 -
Profile // PharmaVoice 100
Tech Wizards: Dominique Demolle
How the CEO of Cognivia is revolutionizing drug development with psychonomics.
By PharmaVoice staff • Sept. 6, 2022 -
Profile // PharmaVoice 100
Innovators: Dr. Judith Klimovsky
The executive vice president and chief business officer of Genmab is using decades of experience in oncology R&D to fuel advances in antibody-drug conjugates.
By Meagan Parrish • Sept. 6, 2022 -
Profile // PharmaVoice 100
Innovators: Dr. Jula Inrig
The longtime devotee to kidney disease research is using a novel trial design to advance treatments for rare conditions at Travere.
By Meagan Parrish • Sept. 6, 2022 -
Profile // PharmaVoice 100
Legacy Leaders: Dr. Michael Hayden
The CEO at Prilenia has an unwavering dedication to address the needs of HD patients and their families.
By PharmaVoice staff • Sept. 6, 2022 -
Profile // PharmaVoice 100
DE&I Champions: Dr. Pam Diamond
The chief medical officer and co-founder of Curavit Clinical Research is bringing a new level of inclusiveness to clinical trials.
By Meagan Parrish • Sept. 6, 2022 -
Profile // PharmaVoice 100
Entrepreneurs: Samantha Du
The CEO of Zai Lab is at the forefront of the movement to boost innovation in China’s biotech sector while delivering needed solutions to patients around the world.
By Meagan Parrish • Sept. 6, 2022 -
Profile // PharmaVoice 100
Legacy Leaders: Dr. Edward Kaye
The CEO behind the first genetic therapy for Duchenne muscular dystrophy is looking to extend his winning streak at Stoke.
By PharmaVoice staff • Sept. 6, 2022 -
Profile // PharmaVoice 100
Disrupters: Elisha Hughes
The director of research biostatistics at Myriad Genetics is looking to stretch the boundaries of science and change how breast cancer is detected in diverse patient populations.
By PharmaVoice staff • Sept. 6, 2022 -
Profile // PharmaVoice 100
Disrupters: Fahti Khosrowshahi
The president, CEO and founder of Ceek Women’s Health is on a mission to upend the OBGYN market.
By PharmaVoice staff • Sept. 6, 2022 -
Profile // PharmaVoice 100
Disrupters: Faraz Ali
The CEO is leading Tenaya Therapeutics forward in ways that combine people-focused leadership, a strong dedication to patients and bold ideas for the future.
By Alexandra Pecci • Sept. 6, 2022 -
Profile // PharmaVoice 100
Legacy Leaders: Frank Lee
At Forma Therapeutics, the CEO and president is placing patients in leadership roles to weave patient centricity into the company’s business and development model.
By PharmaVoice staff • Sept. 6, 2022 -
Profile // PharmaVoice 100
Disrupters: Giacomo Chiesi
For the head of Chiesi Global Rare Diseases, patient centricity is in his DNA.
By PharmaVoice staff • Sept. 6, 2022 -
Profile // PharmaVoice 100
Tech Wizards: Helen Sabzevari
The CEO of Precigen is on a mission to develop next-generation gene and cell therapies for cancers, autoimmune disorders and more.
By PharmaVoice staff • Sept. 6, 2022 -
Profile // PharmaVoice 100
Legacy Leaders: Dr. Helen Thackray
The chief research and development officer at BioCryst Pharmaceuticals is leaning into decades of experience to advance a promising pipeline of rare disease products.
By PharmaVoice staff • Sept. 6, 2022 -
Profile // PharmaVoice 100
Legacy Leaders: Dr. Henrietta Ukwu
Novavax’s regulatory head helped the company pull off its first approvals with the FDA and the EMA — but her accomplishments in pharma run deep.
By Meagan Parrish • Sept. 6, 2022 -
Profile // PharmaVoice 100
Tech Wizards: Houda Hachad
This inventor and 'entrepreneurial scientist' is developing new technologies to manage data and use insights from genomic testing at AccessDx Laboratory.
By Alexandra Pecci • Sept. 6, 2022 -
Profile // PharmaVoice 100
Disrupters: Dr. Ian Walters
How the CEO of Portage Biotech is steering cancer R&D in a new direction by advancing diverse drug platforms.
By PharmaVoice staff • Sept. 6, 2022 -
Profile // PharmaVoice 100
Disrupters: Dr. Jane Barlow
The executive vice president and chief clinical officer of Real Endpoints is boosting patient access to innovative therapies through value-based payer agreements.
By Meagan Parrish • Sept. 6, 2022